ReviewClinical cancer research : an official journal of the American Association for Cancer Research2019
The Reciprocity between Radiotherapy and Cancer Immunotherapy.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05798845 (Exploratory Phase II Clinical Study of Toripalimab Plus Radiotherapy Versus Toripalimab Plus Chemotherapy for the Neoadjuvant Treatment of Operable Stage II-IIIA), which is not on this map. Cited by 116 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory Phase II Clinical Study of Toripalimab Plus Radiotherapy Versus Toripalimab Plus Chemotherapy for the Neoadjuvant Treatment of Operable Stage II-IIIA (N+) Non-small Cell Lung Cancer (NSCLC)
Who cites it
116 citing papers in PubMed, 3 syntheses or guidelines pooled it, 175 citations in OpenAlex.
- Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.Frontiers in immunology · 2026Pooled it
- Effect ofFrontiers in pharmacology · 2025Pooled it
- Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application.Frontiers in immunology · 2025Pooled it
- Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.Cancer research communications · 2025Trial
- Efficacy and safety of radiotherapy following chemoimmunotherapy in extensive-stage small cell lung cancer: a retrospective comparative cohort study of consolidation versus salvage indications.Journal of thoracic disease · 2026Article
- Safety and Survival Outcomes of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Analysis (NEO-EC-01).Annals of surgical oncology · 2026Observational
- A single-arm, single-center phase II clinical study of concurrent brain radiotherapy combined with tislelizumab and chemotherapy in patients with small-cell lung cancer and brain metastases.Journal of thoracic disease · 2026Article
- Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance.Cancer pathogenesis and therapy · 2026Review
- Article
- Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions.Translational lung cancer research · 2026Review
- PD-1 inhibitors combined with induction chemotherapy followed by chemoradiotherapy in HPV-negative locally advanced head and neck squamous cell carcinoma: a real-world study.Cancer immunology, immunotherapy : CII · 2026Article
- Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer.Future oncology (London, England) · 2026Article
- Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.The oncologist · 2026Article
- The effects of brain radiotherapy combined with immunotherapy and chemotherapy for driver gene-negative non-small-cell lung cancer with brain metastases.Frontiers in oncology · 2026Article
- Near-Infrared Fluorescent Probes Targeting LAG-3 for Guiding Immunomodulation and Efficacy Monitoring of Stereotactic Body Radiotherapy in Liver Cancer.Journal of hepatocellular carcinoma · 2026Article
- A Review on Melanoma Brain Metastases.Current pharmaceutical design · 2026Review
- Efficacy and patient selection of consolidative thoracic radiotherapy following chemoimmunotherapy in ES-SCLC.Frontiers in cell and developmental biology · 2026Article
- Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study.Cancer pathogenesis and therapy · 2025Article
- Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.